- Home
- YMAB vs VYGR Comparison
YMAB vs VYGR Comparison
Compare YMAB & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- VYGR
- Stock Information
- Founded
- YMAB 2015
- VYGR 2013
- Country
- YMAB United States
- VYGR United States
- Employees
- YMAB N/A
- VYGR N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- YMAB Health Care
- VYGR Health Care
- Exchange
- YMAB Nasdaq
- VYGR Nasdaq
- Market Cap
- YMAB 192.4M
- VYGR 165.5M
- IPO Year
- YMAB 2018
- VYGR 2015
- Fundamental
- Price
- YMAB $4.60
- VYGR $2.74
- Analyst Decision
- YMAB Buy
- VYGR Strong Buy
- Analyst Count
- YMAB 11
- VYGR 8
- Target Price
- YMAB $17.55
- VYGR $14.33
- AVG Volume (30 Days)
- YMAB 226.0K
- VYGR 377.3K
- Earning Date
- YMAB 05-13-2025
- VYGR 05-06-2025
- Dividend Yield
- YMAB N/A
- VYGR N/A
- EPS Growth
- YMAB N/A
- VYGR N/A
- EPS
- YMAB N/A
- VYGR N/A
- Revenue
- YMAB $88,658,000.00
- VYGR $66,958,000.00
- Revenue This Year
- YMAB N/A
- VYGR N/A
- Revenue Next Year
- YMAB $16.03
- VYGR $45.34
- P/E Ratio
- YMAB N/A
- VYGR N/A
- Revenue Growth
- YMAB 4.92
- VYGR N/A
- 52 Week Low
- YMAB $3.55
- VYGR $2.65
- 52 Week High
- YMAB $16.11
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- YMAB 56.43
- VYGR 33.88
- Support Level
- YMAB $3.99
- VYGR $2.71
- Resistance Level
- YMAB $5.00
- VYGR $2.99
- Average True Range (ATR)
- YMAB 0.35
- VYGR 0.18
- MACD
- YMAB 0.10
- VYGR -0.05
- Stochastic Oscillator
- YMAB 70.47
- VYGR 10.86
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.